Skip to main content
OpenTrials
Completed

NCT Number: NCT06947486

Correlation of EtCO₂- and P(A-a)O₂-Based Dead Space Calculations in Mechanically Ventilated ICU Patients

This study aims to evaluate two different methods for calculating physiological dead space in adult patients undergoing invasive mechanical ventilation in the intensive care unit (ICU). Physiological dead space refers to the portion of air that is ventilated but does not participate in gas exchange due to impaired perfusion or ventilation-perfusion mismatch.

Traditionally, dead space is calculated using the end-tidal carbon dioxide (EtCO₂) method, which estimates the difference between arterial and exhaled CO₂ values. However, this method may be influenced by circulatory failure or abnormal CO₂ distribution. An alternative method using the alveolar-arterial oxygen gradient [P(A-a)O₂] has been proposed, as it may provide a more stable measurement under critical conditions by relying on oxygenation efficiency rather than CO₂ elimination.

In this prospective observational study, patients receiving mechanical ventilation in a tertiary ICU will be monitored. Physiological dead space will be calculated using both the EtCO₂-based method and the P(A-a)O₂-based method. Various respiratory and clinical parameters, including arterial blood gases, ventilator settings, and severity scores, will be recorded. The correlation between the two methods will be assessed, and their relationship with ICU mortality will be analyzed.

The results of this study may help determine whether the P(A-a)O₂ method can be used as a reliable alternative for estimating dead space in ICU patients and whether it has prognostic value in predicting patient outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Karadeniz Technical University Faculty of Medicine, Department of Chest Diseases, Intensive Care Unit

Trabzon, 61080, Turkey (Türkiye)

About this study

Physiological dead space (VD/VT) is a key parameter in evaluating the efficiency of gas exchange in mechanically ventilated patients. It represents the fraction of each breath that does not participate in effective alveolar ventilation due to perfusion defects, shunt physiology, or mismatched ventilation-perfusion (V/Q) ratios. An elevated dead space fraction has been associated with poor clinical outcomes, especially in patients with acute respiratory failure or circulatory impairment.

The most commonly used method for estimating dead space in the intensive care setting is based on the Enghoff modification of the Bohr equation:

VD/VT = (PaCO₂ - EtCO₂) / PaCO₂

This approach utilizes the arterial carbon dioxide pressure (PaCO₂) and end-tidal carbon dioxide pressure (EtCO₂) to estimate the proportion of ventilation that does not contribute to CO₂ elimination. However, it assumes a relatively homogenous V/Q distribution and may lose accuracy in the presence of increased shunt, circulatory shock, or CO₂ transport abnormalities.

To improve on these limitations, the present study also incorporates the alveolar-arterial oxygen gradient [P(A-a)O₂] as an alternative method for estimating physiological dead space. The gradient is calculated as:

P(A-a)O₂ = PAO₂ - PaO₂, where PAO₂ = FiO₂ × (Patm - PH₂O) - (PaCO₂ / R)

The dead space ratio can then be estimated by a similar structure:

VD/VT = (PAO₂ - PaO₂) / PAO₂

The P(A-a)O₂-based method may offer more robust estimations under critically ill conditions, particularly in cases with oxygenation defects or hemodynamic compromise, as it is less affected by variations in CO₂ distribution or metabolism.

In addition to Enghoff and oxygen-based approaches, this study also evaluates the Kuwabara modification, which adjusts for venous admixture and attempts to more accurately reflect the effective alveolar ventilation in the presence of shunt physiology. Kuwabara and Duncalf introduced a correction to the dead space formula to account for anatomical and functional shunts, reducing potential overestimation caused by disproportionate alveolar ventilation:

Corrected VD/VT = [(PaCO₂ - EtCO₂) / PaCO₂] × α

Where α represents a correction factor that adjusts for venous admixture and other circulatory influences.

This prospective observational study will include adult patients undergoing invasive mechanical ventilation in a tertiary ICU. Participants will be evaluated at multiple time points using volumetric capnography, arterial and venous blood gases, and ventilator-derived parameters. Physiological dead space will be calculated in parallel using:

Enghoff's method

P(A-a)O₂-based oxygenation gradients

Kuwabara correction for venous admixture

Daily clinical scores (SOFA, APACHE II), ventilator mechanics (PEEP, tidal volume, FiO₂, plateau pressure, driving pressure), and gas exchange variables (PaCO₂, PaO₂/FiO₂, VCO₂, VO₂) will also be recorded.

The study aims to assess:

The correlation between the EtCO₂- and P(A-a)O₂-based dead space methods

The influence of shunt and hemodynamic variables on dead space estimation

The prognostic relevance of each method in relation to ICU mortality

This study seeks to contribute to the optimization of dead space measurement in the ICU by evaluating alternative, potentially more reliable physiologic methods. It also aims to inform future clinical practice by identifying the most accurate and clinically useful dead space assessment tools in the context of severe critical illness.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Admission to the intensive care unit (ICU)
  • Receiving invasive mechanical ventilation
  • Expected ICU stay ≥ 24 hours
  • Availability of both arterial blood gas and volumetric capnography measurements
  • Central venous cathater for central venous blood analyses
  • Informed consent obtained from legal representative

Exclusion criteria

  • Refusal of participation by the patient or legal surrogate
  • Hemoglobin < 7 g/dL
  • PaCO₂ > 70 mmHg
  • Lactate > 4 mmol/L
  • Capillary refill time > 3 seconds
  • Mean arterial pressure (MAP) < 65 mmHg
  • Mottling score ≥ 2
  • PaCO₂ - PcCO₂ gradient > 8 mmHg
  • pH < 7.20
  • Body temperature > 38°C
  • BMI > 40 kg/m²
  • VCO₂ > 4 mL/kg/min
  • Technical limitations preventing accurate capnographic monitoring
  • Patients who are extubated, transferred, or deceased within the first 24 hours

Treatment and study plan

Primary outcomes

  1. Correlation between EtCO₂- and P(A-a)O₂-based dead space calculations

    Time frame: Within the first 72 hours of ICU admission

    Description: Pearson or Spearman correlation coefficient calculated between dead space values obtained from EtCO₂ (Enghoff modification) and P(A-a)O₂-based gradient methods in mechanically ventilated ICU patients.

Secondary outcomes

  1. Association of each dead space method with ICU mortality

    Time frame: From ICU admission until ICU discharge or death

    Evaluation of whether EtCO₂- and P(A-a)O₂-derived dead space values are independently associated with ICU mortality.

  2. Agreement between EtCO₂- and P(A-a)O₂-based dead space estimates

    Time frame: Within first 3 days of ICU stay

    Bland-Altman and bias analysis to evaluate agreement between the two measurement methods.

  3. Relationship between dead space values and gas exchange/ perfusion variables

    Time frame: Daily for up to 72 hours

    Correlation between VD/VT and parameters such as PaO₂/FiO₂, lactate, MAP, and mottling score.

Sponsors and collaborators

Lead sponsor

Karadeniz Technical University

Other

Registry information

Official study title

COmparison of Physiological Dead Space Calculations Using EtCO₂ and P(A-a)O₂ in Mechanically Ventilated ICU Patients: A Prospective Observational Study

Acronym: CODE-EtA

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 27, 2025
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.